Corporate Events

Chugai Pharmaceutical Co., Ltd. announced that clinical development of emugrobart (development code: GYM329), a subcutaneously (SC) administered anti-latent myostatin sweeping antibody developed by Roche for obesity will be discontinued and that Roche will end all future development of emugrobart. As a result, all rights previously licensed to Roche with respect to emugrobart will be returned to Chugai, and Chugai has initiated preparation to resume development for spinal muscular atrophy (SMA), while also considering potential out-licensing opportunities. The decision to discontinue development for obesity was based on a comprehensive assessment of the data obtained to date, including the interim analysis from the ongoing Phase II GYMINDA study. In the GYMINDA study, the efficacy and safety of emugrobart in combination with GLP-1/GIP receptor agonists were evaluated in patients with obesity/overweight. It was concluded that achieving the pre-specified efficacy objectives of clinically meaningful weight loss is unlikely. Emugrobart was well tolerated in the study, and no new safety signals were observed. In March 2026, Roche announced the discontinuation of the clinical development of emugrobart for SMA and FSHD (facioscapulohumeral muscular dystrophy). Since then, based on emugrobart’s subcutaneous (SC) administration, obtained safety profile, pharmacodynamics, clinical signals (including long-term data), and Phase III study design modifications, Chugai has identified an opportunity to support a Phase III study in SMA. Chugai has therefore initiated preparations to resume development, while also exploring potential out-licensing opportunities with third parties.

Lasker~DeBakey Clinical Medical Research Award Press Conference

Chugai Pharmaceutical Co., Ltd. has filed a regulatory application with the Ministry of Health, Labour and Welfare for the anti-cancer agent/humanized anti-PD-L1 monoclonal antibody Tecentriq Intravenous Infusion 840mg [generic name: atezolizumab (genetical recombination)] for an additional indication as adjuvant treatment for adults and pediatric patients with microsatellite instability-high (MSI-High) colon cancer. If approved, Tecentriq would become the first immune checkpoint inhibitor in Japan for adjuvant treatment of colon cancer. This filing is based on the results from the investigator-initiated global Phase III ATOMIC trial (Alliance A021502) in patients with pathological Stage III deficient mismatch repair (dMMR) colon cancer following curative resection. The trial evaluated the efficacy and safety of adding Tecentriq to standard adjuvant mFOLFOX6 chemotherapy. dMMR is known to lead to MSI-High status in tumor cells. For the primary endpoint of disease-free survival (DFS), three-year DFS rates were 86.3% (95% CI: 81.8-89.8) in the Tecentriq combination arm and 76.2% (95% CI: 70.9-80.6) in the mFOLFOX6 arm. The Tecentriq combination arm demonstrated a statistically significant improvement compared with mFOLFOX6 alone, reducing the risk of disease recurrence or death (stratified hazard ratio: 0.50, 95% CI: 0.35-0.73; p<0.001). The most common adverse events were hepatic dysfunction (43.9%), skin disorders (33.8%), and hypothyroidism (18.8%). The safety profile was consistent with the known safety profile of Tecentriq, and no new safety signals were identified. ATOMIC is an investigator-initiated overseas Phase III trial being conducted by the Alliance for Clinical Trials in Oncology, a research group supported by the U.S. National Cancer Institute (NCI), in patients with pathological Stage III deficient mismatch repair (dMMR) colon cancer following curative resection. The trial is being conducted as an open-label, randomized trial evaluating the efficacy and safety of a standard adjuvant mFOLFOX6 treatment arm (administered for six months) and a combination treatment arm in which mFOLFOX6 plus Tecentriq is administered for six months, followed by Tecentriq monotherapy for an additional six months (12 months in total). The FDA has granted Priority Review and is expected to make a decision on the approval by 9 October 2026. Tecentriq is an immune checkpoint inhibitor designed to target PD-L1 (programmed death-ligand 1) expressed on tumor cells or tumor-infiltrating immune cells. PD-L1 binds to PD-1 and B7.1 receptors on T cells and suppresses T-cell function. By inhibiting this interaction, Tecentriq is considered to restore T-cell activity and promote immune response against tumor cells. In Japan, Tecentriq was launched in April 2018 and has obtained approval for 7 tumor types (extensive-stage small cell lung cancer, non-small cell lung cancer, breast cancer, hepatocellular carcinoma, alveolar soft part sarcoma, extranodal natural killer/T-cell lymphoma nasal type, and thymic carcinoma).

Phylo, Inc. announced a collaboration with Chugai Pharmaceutical Co., Ltd. to deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's drug discovery workflows. This partnership addresses a familiar bottleneck in modern drug discovery: Analytical work behind every research decision is slow and fragmented, forcing scientists to move constantly between disconnected tools, datasets, and methods. As an Integrated Biology Environment, Biomni Lab brings best-in-class AI capabilities and hundreds of biomedical resources into one workspace, giving each Chugai scientist a collaborator across the discovery process. By connecting with proprietary research data inside Chugai's secure environment, Biomni agents turn that data into stronger hypotheses and better-supported decisions, helping Chugai shorten discovery timelines and improve the probability of success in its programs. Biomni Lab will support Chugai's work across multiple areas of drug discovery, including single-cell analysis, human genetics, disease biology, and target evaluation. Chugai joins Phylo's founding customers, a select group of research organizations defining how agentic AI transforms drug discovery.

Chugai Pharmaceutical Co., Ltd. filed a regulatory application with the Ministry of Health, Labour and Welfare for an additional indication of 'prevention of relapse in MOG antibody-associated disease' for Enspryng [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. Enspryng received forerunner designation in 2023 as a treatment for the disease. If approved, Enspryng would become the first treatment covered by health insurance in Japan for the disease. This filing is based on results from METEOROID, a global phase III clinical study in adults and adolescents (aged 12-17 years) with MOGAD. Development in Japan is conducted by Chugai, and Japanese patients have participated in this study. Enspryng, created by Chugai, is a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, which was the first product developed by applying Chugai's proprietary recycling antibody technology. Recycling antibody technology received 'The Imperial Invention Prize,' the highest honor of the Fiscal Year 2026 National Commendation for Invention. Enspryng is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in approximately 90 countries, including Japan, the United States, and Europe. A global phase III clinical study is currently ongoing in autoimmune encephalitis (AIE). In addition, the U.S. Food and Drug Administration (FDA) has accepted the filing for thyroid eye disease (TED) and granted priority review. MOG antibody-associated disease (myelin oligodendrocyte glycoprotein antibody-associated disease, MOGAD) is an autoimmune disease involving demyelination by which a pathogenic autoantibody, an anti-MOG antibody, binds to MOG, which is expressed on the surface of the myelin sheath in the central nervous system. MOGAD causes inflammation of the optic nerves, spinal cord and brain, with symptoms such as visual impairment, loss of sensation, motor dysfunction and dysuria. Currently, no approved therapies exist for the prevention of relapse in MOGAD, and in about 80% of adult patients, the disease is chronic and characterized by a relapsing course with currently used therapies. The inflammatory cytokine IL-6 may play a role in the pathogenesis of MOGAD by promoting the production of autoantibodies and inducing inflammatory effects. The number of patients in Japan is estimated to be approximately 1,700.

Chugai Pharmaceutical Co., Ltd. announced the dividend of ¥66.00 per share for the second quarter of fiscal year ending December 31, 2026, payable on August 28, 2026 against JPY ¥50.00 per share a year ago.

Chugai Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2026. For the half year, the company reported sales was JPY 566,487 million compared to JPY 511,439 million a year ago. Revenue was JPY 663,331 million compared to JPY 578,463 million a year ago. Net income was JPY 231,749 million compared to JPY 194,389 million a year ago. Basic earnings per share from continuing operations was JPY 140.82 compared to JPY 118.13 a year ago. Diluted earnings per share from continuing operations was JPY 140.82 compared to JPY 118.12 a year ago.

Chugai Information Meeting on Gene Therapy for Duchenne Muscular Dystrophy

Chugai Pharmaceutical Co., Ltd. Presents at 22nd Annual PEGS Boston Summit, May-11-2026 . Venue: Omni Boston Hotel at the Seaport, Boston, Massachusetts, United States. Speakers: Hiroaki Nagano.

Chugai Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported sales was JPY 291,577 million compared to JPY 259,722 million a year ago. Revenue was JPY 321,747 million compared to JPY 288,459 million a year ago. Net income was JPY 115,418 million compared to JPY 97,234 million a year ago. Basic earnings per share from continuing operations was JPY 70.13 compared to JPY 59.09 a year ago. Diluted earnings per share from continuing operations was JPY 70.13 compared to JPY 59.08 a year ago.

Chugai Pharmaceutical Co., Ltd., Board Meeting, Apr 24, 2026. Agenda: To consider and approve the introduction of the trust-based stock compensation system, including the scale and timing of acquisition of the Company's shares.

Chugai Pharmaceutical Co., Ltd., ¥ 66.0, Cash Dividend, Jun-29-2026

Chugai Pharmaceutical Co., Ltd. Presents at The 23rd Annual Meeting of JSMO, Mar-26-2026 04:05 PM. Speakers: Takahiro Mizui, Head of Clinical Development Division.

Chugai Pharmaceutical Co., Ltd. announced that Roche has decided to discontinue the clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin sweeping antibody, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision follows a rigorous assessment of data from the Phase II/III MANATEE study (Part 1) in SMA and the Phase II MANOEUVRE study in FSHD. While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. Specifically, muscle growth and exploratory functional efficacy were neither consistent nor robust enough across study participants to provide sufficient confidence for Phase III development in SMA and FSHD. Emugrobart was well tolerated across both studies, with no serious adverse events or treatment withdrawals. The discontinuation of these studies was not due to safety concerns. As the scientific rationale for continuing to investigate emugrobart in obesity remains strong, this decision does not impact the development of emugrobart in obesity. Obesity is a chronic metabolic disease with symptoms and underlying causes being fundamentally different from neuromuscular conditions like SMA and FSHD. In obesity, muscle quality is not primarily affected by a neurodegenerative (nerve-wasting) or myopathic (muscle-wasting) process and there is generally more myostatin for an anti-myostatin antibody to act on. Consequently, the Phase II development of emugrobart in obesity will continue as planned.

AGM

Chugai Pharmaceutical Co., Ltd. reported earnings results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, the company reported sales was JPY 283,200 million compared to JPY 247,600 million a year ago. Revenue was JPY 346,300 million compared to JPY 302,100 million a year ago. Net income was JPY 128,400 million compared to JPY 91,600 million a year ago. Basic earnings per share from continuing operations was JPY 78.03 compared to JPY 55.64 a year ago. Diluted earnings per share from continuing operations was JPY 78.02 compared to JPY 55.64 a year ago. For the full year, sales was JPY 1,077,803 million compared to JPY 997,901 million a year ago. Revenue was JPY 1,257,941 million compared to JPY 1,170,611 million a year ago. Net income was JPY 434,012 million compared to JPY 387,317 million a year ago. Basic earnings per share from continuing operations was JPY 263.73 compared to JPY 235.39 a year ago. Diluted earnings per share from continuing operations was JPY 263.72 compared to JPY 235.36 a year ago.

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Agenda: To consider appropriation of surplus; to consider election of nine directors; to consider revision of stock compensation system for directors.

Chugai Pharmaceutical Co., Ltd. announced that special year-end dividend for the fiscal year ended December 31, 2025 is planned to be ¥75 per share. Record date is December 26, 2026. The company to propose the dividend at its AGM scheduled to be held on March 26, 2026. Effective date is March 27, 2026.

Chugai Pharmaceutical Co., Ltd. announced that for the following fiscal year ending December 31, 2026, the company expects annual dividends of ¥132, including interim dividends of ¥66. As a result, the Core dividend payout ratio for 2026 is expected to be 44.7% (54.7% on a five-year average basis).

Chugai Pharmaceutical Co., Ltd., Board Meeting, Jan 29, 2026. Agenda: To propose the dividend of retained earnings with a record date of December 31, 2025, to the 115th Annual General Meeting of Shareholders scheduled to be held on March 26, 2026; and to consider other business matters.

Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion on October 24, 2025. A cash consideration of ¥15 billion will be paid by Chugai Pharmaceutical Co., Ltd for Common shares of 5,015,625 shares and Class A Preferred Shares of 4,424,880 shares. Chugai Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of ¥16 billion cash. The expected completion of the transaction is November 30, 2025. As of November 18, 2025, the transaction is expected to complete on November 27, 2025. Chugai Pharmaceutical Co., Ltd. (TSE:4519) completed the acquisition of Renalys Pharma on December 30, 2025.

Chugai Pharmaceutical Co., Ltd. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 08:15 AM. Venue: The Westin St. Francis Hotel, 111 Minna Gallery, 335 Powell Street, San Francisco, California, United States. Speakers: Iwaaki Taniguchi, Executive VP, Head of Finance Supervisory Division, CFO & Director, Osamu Okuda, President, CEO & Chairman, Tomoyuki Igawa, VP & Head of Research Division.

Chugai Pharmaceutical Co., Ltd. Presents at Antibody Engineering & Therapeutics, Dec-14-2025 . Venue: Marriott Marquis San Diego Marina, Pacific Ballroom, San Diego, California, United States. Speakers: Yuri Teranishi-Ikawa, Principal Scientist, Discovery Biologics.

Chugai Pharmaceutical Co., Ltd., Board Meeting, Nov 18, 2025. Agenda: To conduct an absorption-type merger with Renalys Pharma, Inc which Chugai is scheduled to acquire as a wholly-owned subsidiary on November 27, 2025; and to consider other matters with permission of chair.

Winsight, LLC, Antibody Engineering & Therapeutics, Dec 14, 2025 through Dec 18, 2025. Venue: Marriott Marquis San Diego Marina, Pacific Ballroom, San Diego, California, United States.

Chugai Pharmaceutical Co., Ltd., Q1 2026 Earnings Call, Apr 24, 2026

Chugai Pharmaceutical Co., Ltd., 2025 Earnings Call, Jan 29, 2026

Chugai Pharmaceutical Co., Ltd., Q2 2026 Earnings Call, Jul 24, 2026

Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results at 5:00 PM, Tokyo Standard Time on Jan 29, 2026

Chugai Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results at 5:00 PM, Tokyo Standard Time on Apr 24, 2026

Chugai Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results at 4:00 PM, Tokyo Standard Time on Jul 24, 2026

Chugai Pharmaceutical Co., Ltd., Board Meeting, Oct 24, 2025. Agenda: To acquire all shares and stock acquisition rights of Renalys Pharma, Inc. a domestic bioventure company, and thereby obtain the exclusive development and commercialization rights in Japan, South Korea, and Taiwan, for sparsentan, which is being developed mainly for IgA nephropathy.

Sustainability Meeting

Chugai Pharmaceutical Co., Ltd. expected to report Fiscal Year 2025 results on January 30, 2026. This event was calculated by S&P Global (Created on October 13, 2025).